 |
|
0 new discussion posts (80 published)
Sign in to view your progression
|
Overall goal
Provide an update on the clinical and operational management of patients with susceptible and drugresistant TB, with special focus on the shorter MDR/RR-TB regimens, the new anti-TB drugs and their classification, and operational research on modified all oral short treatment regimens.
Course content
The course content outlined below will be tailored to the country situation as well as to the national guidelines for TB and DR-TB. Providing training courses that are close to the everyday realities of the participants and the health workers they supervise are more likely to have a positive impact. The course for DR-TB experts will also have a broader scope in order to ensure they are up to date with the latest global and regional developments in DR-TB.
Week 1
- Objectives for TB and DR-TB care and prevention: globally and nationally;
- TB epidemiology and DR-TB burden in country
- Biological characteristics and conditions of M. tuberculosis growth;
- Definitions and basic concepts in TB and DR-TB;
- Global TB and DR-TB situation
- Conventional Procedures in the Diagnosis of TB
- Clinical and Radiography manifestations of TB and DR-TB
- Conventional laboratory procedures: Smear, culture and Identification of species
- Risk factors for drug resistance
- Classification of DR-TB
Week 2
- Approach to the diagnosis of drug resistant tuberculosis
- The importance of the history of previous drug intake by patient and anti-TB drugs used in country in the past
- Support of the Drug susceptibility testing for management of drug resistant TB. Reliability
- Techniques for rapid diagnosis of drug resistant TB
- Molecular Tests for diagnosis RR/MDR/XDR-TB
- Protocols and algorithms for the Diagnosis of TB and DR-TB
Week 3
- Initial Treatment of TB Principles
- Treatment of MDR-TB according to Pattern of Resistance
- Initial susceptible TB
- Mono and Poly Resistance to INH or RIF
- MDR-TB
- XDR-TB
- Beyond XDR-TB
- Duration of the intensive and continuation phase
- Shorter RR/MDR-TB Regimens
- Rational use of first- and second-line drugs in the MDR/XDR-TB Treatment
- Update of the New and repurposed anti-TB drugs for the treatment of MDR and XDR: Linezolid, Clofazimine, Bedaquiline, Delamanid, Carbapenems, others
- Adverse Reactions to First and Second Line Drugs
Week 4
- ECG in the DR-TB treatment. Cardiac safety
- Audiometry: measurement and interpretation
- Tuberculosis, MDR-/XDR-TB and HIV
- Tuberculosis and MDR-/XDR-TB in special situations: pregnancy, children, contacts, diabetes, other co-morbidities
- Reasoning the best treatment options for a NTP
- What is the best Treatment for the New TB cases?
- Which is the most appropriate approach for:
- Relapses and Lost to follow up to First Line anti-TB regimens
- Failures to First Line anti-TB regimens
- DR-TB Patients in the different scenarios
At the end of the training, participants:
- Know the latest updates for diagnosis of DR-TB;
- Can discuss the pros and cons of the latest diagnostic options for DR-TB;
- Know the latest updates on DR-TB treatment;
- Are able to discuss the most favourable treatment options in different situations;
- Can provide guidance on management of DR-TB patients in special situations;
- Know how to monitor and manage adverse events;
- Recognize the need for efficient and consistent drug supply
Clinicians, laboratory scientists, lecturers and staff from medical and other health training institutions with experience in MDR-TB management
The course consists of four weeks of course work: online pre-recorded sessions that you will have to go through by self-study during the week, and one weekly live session. For each week, the pre-recorded sessions will be uploaded after the live session of the previous week.
The weekly live sessions will be accessed through this Zoom link: https://zoom.us/j/95607289247
The schedule is:
- Thursday 28 January 2021 5:00 – 6:00pm (Manila time)
- Thursday 4 February 2021 5:00 – 6:00pm (Manila time)
- Thursday 11 February 2021 5:00 – 6:00pm (Manila time)
- Thursday 18 February 2021 5:00 – 6:00pm (Manila time)
- Friday 26 February 2021 5:00 – 6:00pm (Manila time)
Attendance to all live sessions is mandatory.
|
Week 0 - Introduction to Course
|
|
|
Week 1 - Epidemiology and Clinical Characteristics
|
|
|
Week 2 - Diagnostics & Treatment Principles
|
|
|
Week 3: Treatment of DR-TB
|
|
|
Week 4: Managing Side-effects
|
|
|
Post-assessment & Evaluation
|
|